CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 6967 result(s)

The efficacy of tacrine and the measurement of outcomes in Alzheimer’s disease

Last Updated: January 1, 1997
Result type: Reports

Cite as: Glennie JL. The efficacy of tacrine and the measurement of outcomes in Alzheimer's disease. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 1997. Background Alzheimer's disease (AD) is a disorder associated with progressive decline in memory and cognitive function. It is the most common cause of dementi...

Coronary Stents: Clinical Experience and Cost-effectiveness

Last Updated: January 1, 1997
Result type: Reports

Cite as: Noorani HZ. Coronary stents: clinical experience and cost-effectiveness. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 1997. Coronary stents are of value for the treatment of acute or threatened coronary artery closure complicating PTCA. Short-term clinical and angiographic outcomes are comparable with...

Macrolides in Community-acquired Pneumonia and Otitis Media

Last Updated: January 1, 1997
Result type: Reports

Cite as: Perras C. Macrolides in community-acquired pneumonia and otitis media. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 1997. Background The use of erythromycin is limited by its side effect profile, its weak activity against gram negative pathogens and its dosing schedule. In comparison, azithromycin an...

HMG-CoA reductase inhibitors: a review of published clinical trials and pharmacoeconomic evaluations

Last Updated: January 1, 1997
Result type: Reports

The present study is a review of published clinical trials and pharmacoeconomic evaluations of lipid-lowering agents, focusing mainly on HMG-CoA reductase inhibitors. This review is summarized throughout the text by summary points and propositions. The report discusses the relationship between lipids and coronary events. It then examines the im...

Selective serotonin reuptake inhibitors (SSRIs) for major depression. Part I: evaluation of the clinical literature

Last Updated: January 1, 1997
Result type: Reports

162 randomized controlled trials that compare selective serotonin reuptake inhibitors (SSRIs) to placebo or other antidepressants were reviewed. Meta-analyses were undertaken to compare (i) efficacy, (ii) completion rates, and (iii) adverse effects of individual drugs and drug classes. Efficacy (as measured by change in the Hamilton Rate Scale ...

Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia

Last Updated: January 1, 1997
Result type: Reports

Cite as: Glennie JL. Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 1997. Background Schizophrenia is a prevalent psychiatric disorder with extremely high direct, indirect, and intangible cos...

Selective serotonin reuptake inhibitors (SSRIS) for major depression. Part II: The cost-effectiveness of SSRIs in treatment of depression

Last Updated: January 1, 1997
Result type: Reports

Recent years have witnessed large increases in expenditures on antidepressants. This has coincided with the introduction and the widespread use of a new class of antidepressants, the selective serotonin reuptake inhibitors (SSRIs). SSRIs are substantially more expensive than the older tricyclic antidepressants (TCAs), but have a different advers...

Clinical and economic considerations in the use of fluoroquinolones

Last Updated: January 1, 1997
Result type: Reports

Cite as: Glennie JL. Clinical and economic considerations in the use of fluoroquinolones. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 1997. Background Fluoroquinolones (also generally referred to as "quinolones") are a class of antimicrobial drugs which, as a group, have a broad spectrum of activity against ...